Elraglusib

Actuate Therapeutics received EMA's OMPD for elraglusib, targeting pancreatic ductal adenocarcinoma. A Phase II trial shows improved survival rates with elraglusib combined with GnP, indicating significant clinical benefits and anti-tumour activity. The company aims to advance elraglusib as a novel treatment, with topline data expected in 1H 2025.

Actuate Therapeutics received EMA orphan designation for elraglusib, targeting pancreatic ductal adenocarcinoma. A Phase II trial showed improved survival rates with elraglusib combined with GnP, indicating significant clinical benefit and anti-tumour activity. Elraglusib targets tumour growth pathways and immune regulation, aiming to advance as a novel mPDAC treatment.

Actuate Therapeutics' elraglusib, a GSK-3β inhibitor, received EMA Orphan Medicinal Product Designation for treating pancreatic ductal adenocarcinoma (PDAC). Positive Phase 2 trial results show significant clinical benefits, aiming to expedite elraglusib's development as a novel treatment for metastatic PDAC.

Actuate Therapeutics' elraglusib, a GSK-3β inhibitor, received EMA Orphan Medicinal Product Designation for treating pancreatic ductal adenocarcinoma (PDAC). Positive Phase 2 trial results showed significant clinical benefits, aiming to expedite elraglusib's development as a novel mPDAC treatment.

Actuate Therapeutics' elraglusib, a GSK-3β inhibitor, received EMA Orphan Medicinal Product Designation for treating pancreatic ductal adenocarcinoma (PDAC). Positive Phase 2 trial results showed significant clinical benefits, aiming to expedite elraglusib's development as a novel mPDAC treatment.

Actuate Therapeutics' drug elraglusib received Orphan Medicinal Product Designation from the EMA for treating pancreatic ductal adenocarcinoma. The drug, targeting GSK-3β, shows promising Phase 2 trial results, improving survival rates. Actuate plans to report topline data in 2025, aiming for market exclusivity and reduced fees in the EU.

Actuate Therapeutics' drug elraglusib received EMA's Orphan Medicinal Product Designation for treating pancreatic ductal adenocarcinoma, showing promising Phase 2 trial results. The company plans to report topline data by 2025, aiming for market exclusivity and reduced fees in the EU. Actuate also gained FDA's rare pediatric disease designation for elraglusib for Ewing sarcoma.

Actuate Therapeutics' elraglusib, a GSK-3beta inhibitor, received EMA Orphan Medicinal Product Designation for pancreatic ductal adenocarcinoma treatment, highlighting its potential to meet a critical need for patients with this aggressive disease.

Actuate Therapeutics received EMA Orphan Medicinal Product Designation for elraglusib, a GSK-3β inhibitor, for pancreatic cancer treatment. Elraglusib showed significant clinical benefits in Phase 2 trials, potentially expediting its development as a novel treatment for metastatic pancreatic cancer.